Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia

Abstract Aim Palivizumab has proven effective in reducing hospitalizations, preventing severe illness, improving health outcomes, and reducing healthcare costs for infants at risk of respiratory syncytial virus (RSV) infection. We aim to assess the value of palivizumab in preventing RSV infection in...

Full description

Bibliographic Details
Main Authors:	Jaime E. Ordóñez, Victor M. Huertas
Format:	Article
Language:	English
Published:	BMC 2024-04-01
Series:	BMC Infectious Diseases
Subjects:	Respiratory syncytial viruses Premature birth Bronchopulmonary dysplasia Congenital heart defects Palivizumab Respiratory sounds
Online Access:	https://doi.org/10.1186/s12879-024-09300-5

Similar Items

Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era
by: Bernhard Resch, et al.
Published: (2017-04-01)

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States
by: Tianzhou Yu, et al.
Published: (2024-03-01)

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
by: Mariana Bueno Manini, et al.

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
by: Bernhard Resch
Published: (2017-09-01)

Regional impact of prophylaxis with the monoclonal antibody palivizumab on ospitalizations from respiratory syncytial virus in infants
by: Swiss Medical Weekly
Published: (2001-03-01)

Evaluation of respiratory complications in a cohort of preterm infants who did not receive palivizumab monoclonal antibodies
by: Poliana Castro de Resende Bonati, et al.
Published: (2022-10-01)

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
by: Hasindu S. Edirisinghe, et al.
Published: (2023-11-01)

Respiratory syncytial virus outbreak in neonatal intensive care unit: Impact of infection control measures plus palivizumab use
by: Silva Camila de A, et al.
Published: (2012-05-01)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
by: Roseane Porfírio de Souza, et al.
Published: (2019-08-01)

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
by: Natividad Viguria, et al.
Published: (2021-06-01)

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia
by: Li-Ching Fang, MD, et al.
Published: (2023-11-01)

Palivizumab e virus respiratorio sinciziale: una panoramica
by: Paolo Manzoni
Published: (2011-07-01)

Patient equity and respiratory syncytial virus Immunoprophylaxis
by: H. Cody Meissner
Published: (2019-01-01)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
by: Antonino Capizzi, et al.
Published: (2017-08-01)

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
by: Rodica Gilca, et al.
Published: (2020-12-01)

Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain
by: Ralph Schmidt, et al.
Published: (2017-12-01)

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation
by: D Wang, et al.
Published: (2008-12-01)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
by: Abushahin A, et al.
Published: (2018-01-01)

Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: systematic review and additional economic modelling of subgroup analyses
by: D Wang, et al.
Published: (2011-01-01)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
by: Alessandro Rocca, et al.
Published: (2021-04-01)

Clinical Features of Respiratory Syncytial Virus Infection in Neonates: A Single Center Study
by: Sung Hui Chang, et al.
Published: (2018-11-01)

Resurgence of Respiratory Syncytial Virus in Children: An Out-of-Season Epidemic in Portugal
by: Ana Rita Torres, et al.
Published: (2023-01-01)

Respiratory syncytial virus seasonality in Brazil: implications for the immunisation policy for at-risk populations
by: André Ricardo Ribas Freitas, et al.
Published: (2016-01-01)

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children
by: Saleh al-Alaiyan, et al.
Published: (2015-02-01)

RESPIRATORY SYNCYTIAL VIRUS INFECTION IN INFANTS
by: K. V. YEVDOKIMOV, et al.
Published: (2017-05-01)

Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease
by: Shuenn-Nan Chiu, et al.
Published: (2022-01-01)

Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing
by: Kimpen Jan LL
Published: (2002-06-01)

Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link
by: Piedimonte Giovanni
Published: (2002-06-01)

A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation
by: Turti Tatyana V, et al.
Published: (2012-09-01)

Temporal-spatial analysis of hospitalizations for bronchiolitis in Brazil: prediction of epidemic regions and periods for immunization against the Respiratory Syncytial Virus
by: Edilenia Queiroz Pereira, et al.
Published: (2023-03-01)

Respiratory symptoms in preterm infants: burden of disease in the first year of life
by: Pramana IA, et al.
Published: (2011-05-01)

Murine Neonatal Oxidant Lung Injury: NRF2-Dependent Predisposition to Adulthood Respiratory Viral Infection and Protection by Maternal Antioxidant
by: Hye-Youn Cho, et al.
Published: (2021-11-01)

Exome sequencing identifies gene variants and networks associated with extreme respiratory outcomes following preterm birth
by: Aaron Hamvas, et al.
Published: (2018-10-01)

Detection of the Onset of the Epidemic Period of Respiratory Syncytial Virus Infection in Japan
by: Hidetomi Yamagami, et al.
Published: (2019-03-01)

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010
by: Jesse Papenburg, et al.
Published: (2012-01-01)

Early High-Dose Caffeine Improves Respiratory Outcomes in Preterm Infants
by: Vineet Lamba, et al.
Published: (2021-06-01)

Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports
by: Renato Cutrera, et al.
Published: (2019-11-01)

Survival of recombinant monoclonal and naturally-occurring human milk immunoglobulins A and G specific to respiratory syncytial virus F protein across simulated human infant gastrointestinal digestion
by: Jiraporn Lueangsakulthai, et al.
Published: (2020-10-01)

Preterm birth impairs postnatal lung development in the neonatal rabbit model
by: Thomas Salaets, et al.
Published: (2020-02-01)